U.S. court permits generic version of Teva MS drug a year sooner

WASHINGTON/NEW YORK (Reuters) - Teva Pharmaceutical Industries' $4 billion-a-year multiple sclerosis drug Copaxone will lose its patent protection in 2014 rather than 2015 because of a ruling from a U.S. appeals court on Friday, making it potentially prey to cheaper generics next May.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news